ACM
HUMA icon

Altium Capital Management’s Humacyte HUMA Stock Holding History

Altium Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-275,000
Closed -$2.8M – 137
2021
Q2 		$2.8M Buy
+275,000
New +$2.83M 0.65% 64

Other funds holding HUMA

YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCP
Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Altium Capital Management's HUMA Position: Q3 2021 in Review

Altium Capital Management sold out of Humacyte (HUMA) in Q3 2021, closing a stake of 275,000 shares — an estimated $2.8M sold.

Altium Capital Management first reported a position in HUMA in Q2 2021 and held it in 1 quarter. The position peaked at $2.8M in Q2 2021. 32 funds tracked by Wall St. Rank hold HUMA as of Q3 2021.

  • Altium Capital Management reported no remaining Humacyte position as of Q3 2021 after selling out during the quarter.
  • Altium Capital Management sold 275,000 Humacyte shares in Q3 2021, an estimated $2.8M.
  • Altium Capital Management first reported a position in Humacyte in Q2 2021 and held it in 1 quarter.
  • Altium Capital Management's Humacyte position peaked at $2.8M in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Humacyte as of Q3 2021.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.